COMPANY HISTORY

• The company was founded in April of 2002 as BioCell Innovations.
• In May of 2002 the company acquired its original patent licensing rights through a novation from NASA.*
• In May of 2002 Regenetech® entered into a Sponsored Research Agreement with M.D. Anderson Cancer Center in Houston, Texas.
• Regenetech® filed its first patents in August 2002.
• The company name was changed to Regenetech®, Inc. in November of 2002 in order to begin developing trade name value.
• Stage 1 research was fully completed in January 2003.
• Regenetech® licensed its first intellectual property for treatment of Sickle Cell Anemia.
• In April 2004 Regenetech® Licensed an additional two (2) patents from NASA relating to advanced bioreactor technology.
• In April 2004 Regenetech® entered into a Reimbursable Space Act Agreement with NASA to continue development of adult stem cell expansion.
• In January 2005 Regenetech® confirmed its significantly expanded adult stem cells were free from cancer risks and had no genetic modification.
• In 2005-2006, Regenetech expanded its research at NASA and several universities and completed the filing of its 73 patent applications.

*Research on the Regenetech NASA licensed bioreactor went as far back as shuttle STS-95 with John Glenn's work.